olmesartan has been researched along with cisapride in 2 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (cisapride) | Trials (cisapride) | Recent Studies (post-2010) (cisapride) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 1,554 | 390 | 110 |
| Protein | Taxonomy | olmesartan (IC50) | cisapride (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.767 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 3.37 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.3 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0098 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 3.5923 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.07 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.1701 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.35 | |
| Dipeptidyl peptidase 4 | Rattus norvegicus (Norway rat) | 2.69 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0098 | |
| Insulin receptor | Rattus norvegicus (Norway rat) | 3.37 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 2.29 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 3.3827 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 3.26 | |
| D | Rattus norvegicus (Norway rat) | 0.0065 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 3.6495 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0065 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 1.7 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0065 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0065 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 2.29 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.0065 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.083 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0054 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.2597 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 3.6495 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 4.47 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 4.47 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0098 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.384 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.03 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 3.37 | |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | 0.03 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.144 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.9 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0407 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 2.29 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.535 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.2536 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 0.1701 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.994 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
2 other study(ies) available for olmesartan and cisapride
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |